LNTH - Lantheus soars on FDA approval for PET imaging agent to identify prostate cancer

Lantheus Holdings (LNTH) has climbed ~21.0% in the premarket after announcing the FDA approval for PYLARIFY in the identification of suspected metastasis or recurrence of prostate cancer.PYLARIFY is an F 18-labeled prostate-specific membrane antigen ((PSMA)) targeted positron emission tomography ((PET)) imaging agent. It is “the first and only commercially available approved PSMA PET imaging agent for prostate cancer,” according to the company.The product will be made available immediately in parts of mid-Atlantic and southern regions before a rapid rollout over the next six months for broader availability across the U.S. by the year-end, the company said.“We believe PYLARIFY represents a paradigm shift in the identification and management of patients with suspected metastasis or recurrent prostate cancer, providing more accurate and earlier detection of disease than conventional imaging,” noted Anne Heino CEO of Lantheus.In March, Lantheus announced the acquisition of worldwide rights for NTI-1309, a PET oncology imaging agent from Noria Therapeutics.

For further details see:

Lantheus soars on FDA approval for PET imaging agent to identify prostate cancer